Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments

Archive ouverte

Chevalier, Benjamin | Jannin, Arnaud | Stephanie, Espiard | Merlen, Emilie | Beron, Amandine | Lion, Georges | Vantyghem, Marie-Christine | Huglo, Damien | Cortet-Rudelli, Christine | Baillet, Clio

Edité par CCSD ; Elsevier Masson [1983-....] -

International audience. In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion